Michael Barbella, Managing Editor10.16.23
Microbot Medical Inc. has expanded its global team of expertsby appointing Francois H. Cornelis, M.D., Ph.D., to its Scientific Advisory Board (SAB).
Cornelis is an interventional radiologist who specializes in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumor control in the bones and spine. Professor Cornelis uses a variety of technologies to treat tumors and cancer-related pain, such as radiofrequency and microwave energy, cryotherapy, focused ultrasound, and electroporation, as well as image-guided modalities, including navigation software, MRI, robotics, and PET-CT-guided procedures. He is pursuing research, mainly into intra-arterial therapies for brain tumors and in the fields of mentoplasty, osteoplasty, and fixation - which help reinforce bones to reduce pain.
Cornelis received his medical degree in 2003 and completed his radiology training and his fellowship in 2008 and 2010, respectively, at the University of Bordeaux in France. He stayed on the faculty, with appointments in radiology at the Bergonié Institute (2010) and the University of Bordeaux (2012). He was appointed as a tenured professor of radiology in France in 2017 and served as chief of the Department of Interventional Radiology and Oncology at the Sorbonne University in Paris before heading to New York.
“The support and endorsement of a global leader such as Professor Cornelis is a vote of confidence and a great honor for the company. Professor Cornelis joins a team of global leaders in their fields that are already serving as members of our SAB,” Microbot Medical Chief Medical Officer Dr. Eyal Morag said. “The contributions of our SAB members to the company, including their participation in our pre-clinical studies, is expected to greatly support our forthcoming plans, including clinical trials and collaborations with medical centers worldwide.”
Microbot Medical Inc. is a pre-clinical medical device company that specializes in transformational micro-robotic technologies to improve clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body. The LIBERTY Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The company claims the LIBERTY Robotic Surgical System’s remote operation can potentially be the first system to democratize endovascular interventional procedures.
Cornelis is an interventional radiologist who specializes in neuro interventions and image-guided minimally invasive therapies that allow for pain palliation and tumor control in the bones and spine. Professor Cornelis uses a variety of technologies to treat tumors and cancer-related pain, such as radiofrequency and microwave energy, cryotherapy, focused ultrasound, and electroporation, as well as image-guided modalities, including navigation software, MRI, robotics, and PET-CT-guided procedures. He is pursuing research, mainly into intra-arterial therapies for brain tumors and in the fields of mentoplasty, osteoplasty, and fixation - which help reinforce bones to reduce pain.
Cornelis received his medical degree in 2003 and completed his radiology training and his fellowship in 2008 and 2010, respectively, at the University of Bordeaux in France. He stayed on the faculty, with appointments in radiology at the Bergonié Institute (2010) and the University of Bordeaux (2012). He was appointed as a tenured professor of radiology in France in 2017 and served as chief of the Department of Interventional Radiology and Oncology at the Sorbonne University in Paris before heading to New York.
“The support and endorsement of a global leader such as Professor Cornelis is a vote of confidence and a great honor for the company. Professor Cornelis joins a team of global leaders in their fields that are already serving as members of our SAB,” Microbot Medical Chief Medical Officer Dr. Eyal Morag said. “The contributions of our SAB members to the company, including their participation in our pre-clinical studies, is expected to greatly support our forthcoming plans, including clinical trials and collaborations with medical centers worldwide.”
Microbot Medical Inc. is a pre-clinical medical device company that specializes in transformational micro-robotic technologies to improve clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body. The LIBERTY Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The company claims the LIBERTY Robotic Surgical System’s remote operation can potentially be the first system to democratize endovascular interventional procedures.